

Amed Ouattara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8121590/publications.pdf>

Version: 2024-02-01

43
papers

2,029
citations

304743

22
h-index

254184

43
g-index

47
all docs

47
docs citations

47
times ranked

2318
citing authors

#	ARTICLE	IF	CITATIONS
1	A Field Trial to Assess a Blood-Stage Malaria Vaccine. <i>New England Journal of Medicine</i> , 2011, 365, 1004-1013.	27.0	311
2	False-Negative Rapid Diagnostic Tests for Malaria and Deletion of the Histidine-Rich Repeat Region of the hrp2 Gene. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 86, 194-198.	1.4	241
3	Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development. <i>Science Translational Medicine</i> , 2009, 1, 2ra5.	12.4	154
4	Space-time clustering of childhood malaria at the household level: a dynamic cohort in a Mali village. <i>BMC Public Health</i> , 2006, 6, 286.	2.9	123
5	Dynamics of Polymorphism in a Malaria Vaccine Antigen at a Vaccine-Testing Site in Mali. <i>PLoS Medicine</i> , 2007, 4, e93.	8.4	94
6	Polymorphisms in the K13-Propeller Gene in Artemisinin-Susceptible <i>Plasmodium falciparum</i> Parasites from Bougoula-Hameau and Bandiagara, Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 1202-1206.	1.4	89
7	Population structure of the genes encoding the polymorphic <i>Plasmodium falciparum</i> apical membrane antigen 1: Implications for vaccine design. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7857-7862.	7.1	83
8	Molecular Basis of Allele-Specific Efficacy of a Blood-Stage Malaria Vaccine: Vaccine Development Implications. <i>Journal of Infectious Diseases</i> , 2013, 207, 511-519.	4.0	66
9	Vaccines Against Malaria. <i>Clinical Infectious Diseases</i> , 2015, 60, 930-936.	5.8	62
10	Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. <i>Malaria Journal</i> , 2010, 9, 175.	2.3	61
11	Strains used in whole organism <i>Plasmodium falciparum</i> vaccine trials differ in genome structure, sequence, and immunogenic potential. <i>Genome Medicine</i> , 2020, 12, 6.	8.2	61
12	A novel method for extracting nucleic acids from dried blood spots for ultrasensitive detection of low-density <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> infections. <i>Malaria Journal</i> , 2017, 16, 377.	2.3	56
13	Designing malaria vaccines to circumvent antigen variability. <i>Vaccine</i> , 2015, 33, 7506-7512.	3.8	54
14	Molecular Diagnosis of Resistance to Antimalarial Drugs during Epidemics and in War Zones. <i>Journal of Infectious Diseases</i> , 2004, 190, 853-855.	4.0	52
15	<i>Plasmodium vivax</i> Infections over 3 Years in Duffy Blood Group Negative Malians in Bandiagara, Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 744-752.	1.4	52
16	Genetic diversity and drug resistance surveillance of <i>Plasmodium falciparum</i> for malaria elimination: is there an ideal tool for resource-limited sub-Saharan Africa?. <i>Malaria Journal</i> , 2019, 18, 217.	2.3	46
17	Evaluation of an Immunofluorescent-Antibody Test Using Monoclonal Antibodies Directed against <i>Enterocytozoon bienersi</i> and <i>Encephalitozoon intestinalis</i> for Diagnosis of Intestinal Microsporidiosis in Bamako (Mali). <i>Journal of Clinical Microbiology</i> , 2002, 40, 1715-1718.	3.9	42
18	Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial. <i>PLoS ONE</i> , 2013, 8, e79323.	2.5	38

#	ARTICLE	IF	CITATIONS
19	A RANDOMIZED TRIAL OF ARTESUNATEâ€“SULFAMETHOXYPYRAZINEâ€“PYRIMETHAMINE VERSUS ARTEMETHERâ€“LUMEFANTRINE FOR THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN MALI. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 75, 630-636.	1.4	32
20	Children with cerebral malaria or severe malarial anaemia lack immunity to distinct variant surface antigen subsets. <i>Scientific Reports</i> , 2018, 8, 6281.	3.3	31
21	Reduced ex vivo susceptibility of <i>Plasmodium falciparum</i> after oral artemetherâ€“lumefantrine treatment in Mali. <i>Malaria Journal</i> , 2017, 16, 59.	2.3	27
22	Prevalence and patterns of antifolate and chloroquine drug resistance markers in <i>Plasmodium vivax</i> across Pakistan. <i>Malaria Journal</i> , 2013, 12, 310.	2.3	24
23	Microarray analyses reveal strain-specific antibody responses to <i>Plasmodium falciparum</i> apical membrane antigen 1 variants following natural infection and vaccination. <i>Scientific Reports</i> , 2020, 10, 3952.	3.3	24
24	A randomized trial of artesunate-sulfamethoxy-pyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 75, 630-6.	1.4	24
25	Antibodies to Peptides in Semiconserved Domains of RIFINs and STEVORs Correlate with Malaria Exposure. <i>MSphere</i> , 2019, 4, .	2.9	23
26	Variation in the Circumsporozoite Protein of <i>Plasmodium falciparum</i> : Vaccine Development Implications. <i>PLoS ONE</i> , 2014, 9, e101783.	2.5	22
27	Seroreactivity to <i>Plasmodium falciparum</i> Erythrocyte Membrane Protein 1 Intracellular Domain in Malaria-Exposed Children and Adults. <i>Journal of Infectious Diseases</i> , 2013, 208, 1514-1519.	4.0	20
28	Seroreactivity to a Large Panel of Field-Derived <i>Plasmodium falciparum</i> Apical Membrane Antigen 1 and Merozoite Surface Protein 1 Variants Reflects Seasonal and Lifetime Acquired Responses to Malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 9-12.	1.4	20
29	Prevalence of molecular markers of sulfadoxineâ€“pyrimethamine and artemisinin resistance in <i>Plasmodium falciparum</i> from Pakistan. <i>Malaria Journal</i> , 2018, 17, 471.	2.3	17
30	Use of a pLDH-based dipstick in the diagnostic and therapeutic follow-up of malaria patients in Mali. <i>Malaria Journal</i> , 2011, 10, 345.	2.3	13
31	Differential Recognition of Terminal Extracellular <i>Plasmodium falciparum</i> VAR2CSA Domains by Sera from Multigravid, Malaria-Exposed Malian Women. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 1190-1194.	1.4	11
32	Extent and Dynamics of Polymorphism in the Malaria Vaccine Candidate <i>Plasmodium falciparum</i> Reticulocyteâ€“Binding Protein Homologue-5 in Kalifabougou, Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 43-50.	1.4	10
33	Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with <i>Plasmodium falciparum</i> apical membrane antigen 1 vaccine candidate FMP2.1/AS02A. <i>Malaria Journal</i> , 2019, 18, 13.	2.3	8
34	Serologic responses to the PfEMP1 DBL-CIDR head structure may be a better indicator of malaria exposure than those to the DBL-Î± tag. <i>Malaria Journal</i> , 2019, 18, 273.	2.3	6
35	Epitope-based sieve analysis of <i>Plasmodium falciparum</i> sequences from a FMP2.1/AS02A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants. <i>Vaccine</i> , 2020, 38, 5700-5706.	3.8	5
36	Whole-genome analysis of Malawian <i>Plasmodium falciparum</i> isolates identifies possible targets of allele-specific immunity to clinical malaria. <i>PLoS Genetics</i> , 2021, 17, e1009576.	3.5	4

#	ARTICLE	IF	CITATIONS
37	Successful Profiling of <i>Plasmodium falciparum</i> Gene Expression in Clinical Samples via a Custom Capture Array. <i>MSystems</i> , 2021, 6, e0022621.	3.8	4
38	Mother-Newborn Pairs in Malawi Have Similar Antibody Repertoires to Diverse Malaria Antigens. <i>Vaccine Journal</i> , 2017, 24, .	3.1	3
39	Epitope-Specific Antibody Responses to a <i>Plasmodium falciparum</i> Subunit Vaccine Target in a Malaria-Endemic Population. <i>Journal of Infectious Diseases</i> , 2021, 223, 1943-1947.	4.0	3
40	Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome. <i>Npj Vaccines</i> , 2021, 6, 115.	6.0	2
41	Differential Incidence of Malaria in Neighboring Villages in a High-Transmission Setting of Southern Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 1209-1214.	1.4	2
42	An In Silico Analysis of Malaria Pre-Erythrocytic-Stage Antigens Interpreting Worldwide Genetic Data to Suggest Vaccine Candidate Variants and Epitopes. <i>Microorganisms</i> , 2022, 10, 1090.	3.6	2
43	#63: Antibodies to Peptides Representing <i>Plasmodium falciparum</i> Circumsporozoite Protein Reflect Acquisition of Naturally Acquired Immunity in Malian Adults and Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, S10-S12.	1.3	0